Press "Enter" to skip to content

Noxopharm’s pre-clinical study confirms that adding Veyonda to LuPSMA Therapy shows survival benefits

As the preclinical studies of the company have shown survival benefits in prostate cancer, the company now sees the product as a major commercial future in the rapidly evolving field of radioligand therapy.The company is confident that the products are capable of showing positive results not only in prostate cancer but also in other wide range of cancers. The company’s pre-clinical studies confirmed that the use of Veyonda in the LuPSMA therapy kills cancer causing cells.

The clinical studies were undertaken for 19.7 months with the LuPIN study combined with the Novartis drug. The company now positions the product as a major commercial future in the rapidly evolving field of radioligand therapy and believes that it will support the radioligand therapy market.

The pre-clinical LuPIN trials have shown impressive survival trials in prostate cancer sufferers that have undergone all the therapies but have seen no positive results. The company says, in the LuPSMA therapy Veyonda has played a key role in showing positive outcomes.The Journal of Nuclear Medicine, one of the most highly respected journals contains a detailed study of the pre-clinical trials.

The company states that the LuPSMA had shown positive results but after adding Veyonda the pre-clinical trial results were more impressive as the tumours almost disappeared. Thus, the company see the successful trial results as a commercial opportunity. Many companies Noxopharm are developing drugs for killing cancer cells causing prostate cancer.

Comments are closed.